secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001558370-24-008133
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO Q1 net loss $11.8M; Phase 2b CHASE trial enrolling, topline data by year-end 2024
--------------------------------------------------------------------------------

- Phase 2b CHASE trial of KPI-012 for PCED enrolling; topline data expected by year-end 2024.
- Cash and equivalents $48.5M as of March 31, 2024; with CIRM award, funds operations into Q3 2025.
- Q1 2024 net loss $11.8M ($4.20/share) vs $14.5M ($6.99/share) in Q1 2023; operating loss $11.9M.
- R&D expenses rose to $6.4M from $4.0M year-over-year, driven by KPI-012 development.
- Gross proceeds of $8.6M from March 2024 private placement partially offset cash used in ops.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024008133/0001558370-24-008133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024008133/kala-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer